| Characteristic | Share of total biologic sales |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Source
Sources
Release date
May 2020
More information
Region
Canada
Survey time period
2018
Supplementary notes
* Annual treatment costs are based
on average annual per beneficiary costs
for public and private plans.
** Expensive drugs for rare diseases
(EDRDs) are defined as medicines
having an FDA or EMA orphan
designation and an annual treatment
cost greater than $100,000 for nononcology
medicines or $7,500 per 28-
day course of treatment for oncology
medicines.
Citation formats
